Literature DB >> 9774279

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

I Viard1, P Wehrli, R Bullani, P Schneider, N Holler, D Salomon, T Hunziker, J H Saurat, J Tschopp, L E French.   

Abstract

Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774279     DOI: 10.1126/science.282.5388.490

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  159 in total

1.  No eczema without keratinocyte death.

Authors:  T Schwarz
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis.

Authors:  A Trautmann; M Akdis; D Kleemann; F Altznauer; H U Simon; T Graeve; M Noll; E B Bröcker; K Blaser; C A Akdis
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

3.  Recurrent skin peeling following Kawasaki disease.

Authors:  C Michie; V Kinsler; R Tulloh; S Davidson
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

Review 4.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 5.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

6.  Multiple skin bullae.

Authors:  Suad Al-Abri; Nabil Al-Zadjali; Abdulla Al-Reesi
Journal:  Oman Med J       Date:  2008-04

Review 7.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

8.  Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.

Authors:  Lisa M Wheatley; Marshall Plaut; Julie M Schwaninger; Aleena Banerji; Mariana Castells; Fred D Finkelman; Gerald J Gleich; Emma Guttman-Yassky; Simon A K Mallal; Dean J Naisbitt; David A Ostrov; Elizabeth J Phillips; Werner J Pichler; Thomas A E Platts-Mills; Jean-Claude Roujeau; Lawrence B Schwartz; Lauren A Trepanier
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

Review 9.  Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review.

Authors:  Olivia A Charlton; Victoria Harris; Kevin Phan; Erin Mewton; Chris Jackson; Alan Cooper
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-01-09       Impact factor: 4.730

Review 10.  The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade.

Authors:  Nina Svetlicky; Oscar-Danilo Ortega-Hernandez; Luc Mouthon; Loic Guillevin; Hans-Jurgen Thiesen; Arie Altman; Martine Szyper Kravitz; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2012-12-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.